Abstract
In recent years, there have been concerted efforts to enhance the precision of
disease diagnosis and monitoring as the hetrogeneity of conditions becomes
increasingly understood. Targeting broad patient populations in a
' one-pill-fits-all' approach has begun to attract criticism, with the average
efficacy of such drugs being estimated at 50% or less. In the current climate,
biomarkers have emerged as key tools in the realisation of personalised
medicine by characterizing specific diseases and treatment responses at the
DNA, RNA, protein, or metabolite level. ' The Convergence of Biomarkers and
Diagnostics' is a new report published by Business Insights that provides a
detailed assessment of recent developments and future opportunities for
biomarker companies in all major therapeutic areas. This report analyzes the
markets for diagnostic biomarkers, including currently marketed products and
products in development, and examines current trends in the discovery,
validation and clinical application of biomarkers. Advances in biomarker
detection technologies are profiled and the strategies of companies involved
in biomarker discovery or diagnostic development are assessed. This report
also forecasts growth in biomarker and diagnostic segments to 2012. Identify
the latest developments in diagnostic biomarkers, examine biomarker-related
patent trends and benchmark the strategies used to identify and validate novel
biomarkers with this new report.
View Cart
